RDX5791

DRUG3 trials

Sponsors

Ardelyx

Conditions

Constipation Predominant Irritable Bowel SyndromeHealthy

Phase 1

Safety, Tolerability, and Pharmacodynamics of RDX5791 in Healthy Volunteers

CompletedNCT02796131

Start: 2011-07-31End: 2012-04-30Updated: 2016-06-10

Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RDX5791 in Healthy Volunteers

CompletedNCT02819687

Start: 2010-11-30End: 2011-08-31Updated: 2016-06-30

Phase 2

A Study to Evaluate the Safety and Efficacy of RDX5791 for the Treatment of Constipation Predominant Irritable Bowel Syndrome (IBS-C)

CompletedNCT01340053

ArdelyxConstipation Predominant Irritable Bowel Syndrome

Start: 2011-05-31End: 2012-02-29Updated: 2019-10-15

Related Papers

Pharmacodynamics, Safety, and Tolerability of the NHE3 Inhibitor Tenapanor: Two Trials in Healthy Volunteers.

2018-04-0142 citations